Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
We have reported that cholesterol efflux capacity (CEC) and anti-oxidative activity of high-density lipoprotein in non-nephrotic patients with chronic kidney disease (J Atheroscler Thromb. 2025. doi: 10.5551/jat.65662.). There is little information on abnormalities of high-density lipoprotein (HDL) function in patients with nephrotic syndrome (NS). This study is aimed to explore the alteration of cholesterol efflux capacity and anti-oxidative activity of HDL in patients with nephrotic syndrome.
This retrospective cross-sectional observational study cohort included 515patients who underwent a kidney biopsy at Kitano Hospital. A total of 60 patients with nephrotic syndrome (median age: 60 (42, 68), male (50%) was recruited for the analysis. The remaining were recruited for the propensity score matching to adjust for baseline differences. CEC and oxygen radical adsorption capacity (ORAC) as anti-oxidative capacity were measured using serum obtained at the time of the kidney biopsy. Changes of CEC and ORAC in relation to the clinical and kidney injury parameters were evaluated.
HDL-cholesterol level of patients with nephrotic syndrome was 57 (48.2, 80) mg/dL. CEC and ORAC were 0.778 (0.645, 0.858) and 0.681 (0.605 0.764), respectively. Spearman’s coefficient analysis showed that body mass index (BMI) was significantly associated with CEC (ρ=-0.397, p=0.001) but not with ORAC (ρ=-0.115, p=0.371). Estimated glomerular filtration rate (eGFR) showed moderate association with CEC (ρ=0.453, p<0.001) but not with ORAC (ρ=0.04, p=0.721).
After adjusting for sex, age, statin use, BMI, and eGFR using propensity score matching, no significant difference in CEC was observed between the nephrotic syndrome (n=23) and non-nephrotic syndrome groups (n=23) (0.79 (0.57, 1.22) vs 0.89 (0.39, 1.03), p=0.240); however, ORAC was significantly lower in the nephrotic syndrome group (0.70±0.16 vs 0.86±0.17, p=0.002).
CEC of minimal change nephrotic syndrome (MCNS, n=7) (0.846 (0.825, 0.953)) was significantly higher than diabetic nephropathy (DN, n=16) (0.721 (0.634, 0.759)), p=0.001 and membranous nephropathy (MN, n=12) (0.708 (0.630, 0.801)), p=0.009.
ORAC of MCNS (0.562 (0.528, 0.629) was significantly lower than DN (0.721 (0.634, 0.759)), p=0.001, mesangial proliferative glomerulonephritis (GN, n=13) (0.736 (0.680, 0.865), p=0.018.
A multiple regression analysis showed that lower CEC was associated with higher BMI, lower eGFR and NS excluding MCNS, and that lower ORAC was associated with lower serum albumin and MCNS.
Among the functional properties of HDL, its antioxidative capacity is notably reduced in patients with nephrotic syndrome, especially in MCNS, compared with non-nephrotic syndrome. HDL functional impairment might vary depending on the underlying disease.
